Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396038 | 0.82 | PTGDR2 (0.42) | PTGDR2KDM4EALDH1A1 | |
| SCHEMBL136486 | 0.79 | PTGDR2 (0.46) | PTGDR2KDM4EALDH1A1 | |
| SCHEMBL14629997 | 0.79 | KDM4E (0.43) | PTGDR2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL14630142 | 0.78 | PTGDR2 (0.48) | PTGDR2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL152613 | 0.76 | PTGDR2 (0.52) | PTGDR2 | |
| SCHEMBL13310594 | 0.71 | NOTUM (0.40) | KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL26920637 | 0.71 | NOTUM (0.46) | KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL13428213 | 0.71 | PTGDR2 (0.52) | PTGDR2 | |
| SCHEMBL16501870 | 0.70 | MEN1 (0.49) | PTGDR2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL15475864 | 0.68 | HCRTR1 (0.38) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885KDM4E 4767/4885ALDH1A1 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.